TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search
PRESS RELEASES

ObsEva SA To Participate In JP Morgan Virtual Healthcare Conference January 11 - 14, 2021

PRESS RELEASES

ObsEva Appoints David Renas As Chief Financial Officer

PRESS RELEASES

ObsEva Announces Additional Phase 3 PRIMROSE 1 And 2 Study Results Confirming Sustained Efficacy And Continued Safety Of Linzagolix In The Treatment Of Uterine Fibroids

PRESS RELEASES

ObsEva SA To Present At The International Society Of Gynecological Endocrinology 19th World Congress - Virtual Edition, December 2-5, 2020

PRESS RELEASES

ObsEva SA Submits Marketing Authorization Application To The European Medicines Agency For YSELTY® (linzagolix) For The Treatment Of Women With Uterine Fibroids

PRESS RELEASES

ObsEva SA Reports Positive Topline Results Of The PROLONG Proof-of-Concept Trial Of Ebopiprant (OBE022) For Treatment Of Preterm Labor

PRESS RELEASES

ObsEva SA To Present At Jefferies Virtual London Healthcare Conference, November 17 - 19, 2020

PRESS RELEASES

ObsEva Appoints Brian O'Callaghan As Chief Executive Officer

PRESS RELEASES

ObsEva SA Hosts Live Symposium And Presents Oral Communication At The SEUD Online Week November 3 - 6, 2020

PRESS RELEASES

ObsEva SA Presented Two Late-Breaking Posters At The ASRM 2020 Virtual Scientific Congress October 17-21

PRESS RELEASES

ObsEva SA Presented Nolasiban Poster At The ASRM 2020 Virtual Scientific Congress October 17-21

PRESS RELEASES

ObsEva SA To Present At The H.C Wainwright 22nd Annual Global Investment Virtual Conference, September 14-16, 2020

PRESS RELEASES

ObsEva Announces $20.0 Million Underwritten Offering And Concurrent Private Placement Priced At-The-Market Of Common Shares And 15-Month Purchase Warrants For Potential Additional Gross Proceeds Of $23.9 Million

PRESS RELEASES

ObsEva SA To Present At The Wedbush PacGrow Healthcare Virtual Conference, August 11 - 12, 2020

PRESS RELEASES

ObsEva SA Awarded Clinical Science Award For Oral Presentation At ESHRE Virtual 36th Annual Meeting, July 2020

PRESS RELEASES

ObsEva Announces Positive Results From Two Phase 3 Studies, PRIMROSE 1 And 2, Of Yselty® (linzagolix) For The Treatment Of Uterine Fibroids

PRESS RELEASES

ObsEva SA To Present At ESHRE Virtual 36th Annual Meeting, July 5-8, 2020

PRESS RELEASES

ObsEva And Yuyuan BioScience Technology Announce Submission Of The Pre-IND Dossier For Nolasiban With The Chinese NMPA

PRESS RELEASES

ObsEva SA To Hold Conference Call Monday, July 6 To Discuss Results From Phase 3 PRIMROSE 1 And PRIMROSE 2 Trials Evaluating Linzagolix In Women With Uterine Fibroids

PRESS RELEASES

ObsEva SA Announces That Shareholders Approved All Board Proposals At Its 2020 Annual General Meeting Held On June 9, 2020

PRESS RELEASES

ObsEva Announces Publication Of Data Showing Efficacy Of Linzagolix In A Potential New Indication For Treatment Of Adenomyosis

PRESS RELEASES

ObsEva SA To Present At The Jefferies Virtual Healthcare Conference June 3rd, 2020

PRESS RELEASES

ObsEva Annual General Meeting 2020

PRESS RELEASES

ObsEva Announces Publication Of Abstracts From Phase 2b EDELWEISS Trial Of Linzagolix In Endometriosis